Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119649 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
A Phase 2 study, sponsored by Lakefront Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT03119649: Completed Phase 2 study, sponsored by Lakefront Biotherapeutics.
NCT03119649 is a Phase 2 study that has completed, run by Lakefront Biotherapeutics. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03119649, a Phase 2 study, has completed, sponsored by Lakefront Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to adult subjects with a confirmed diagnosis of CF and homozygous for the F508del Cystic Fibrosis Transmembrane conductance Regulator (CFTR) mutation.
Interventions
- DRUG Placebo
- DRUG GLPG2222 50 mg
- DRUG GLPG2222 100 mg
- DRUG GLPG2222 200 mg
- DRUG GLPG2222 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-03-18 |
| Est. Completion | 2017-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119649
The ClinicalTrials.gov registry entry for NCT03119649 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03119649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03119649 about?
NCT03119649 is a clinical study titled "A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis". This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to adult subjects with a confirmed diagnosis of CF and homozygous for the F508del Cystic Fibrosis Transmembrane conductance Regulat...
What is the current status of trial NCT03119649?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-03-18. Estimated completion is 2017-10-19.
What interventions are being tested in trial NCT03119649?
The interventions under investigation include: Placebo (DRUG), GLPG2222 50 mg (DRUG), GLPG2222 100 mg (DRUG), GLPG2222 200 mg (DRUG), GLPG2222 400 mg (DRUG).
Who is sponsoring clinical trial NCT03119649?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.